OncoResponse, Inc, based in Seattle, WA, is a biotechnology company focused on discovering novel cancer immunotherapies by leveraging elite immune responses. Their mission is to attack cancer by uncovering authentic human antibodies from exceptional responders to checkpoint inhibitor therapies, with a pipeline aimed at enhancing immune activity in the tumor microenvironment.
Utilizing a clinically validated Technology Platform, OncoResponse aims to develop monoclonal antibodies that target immunosuppressive myeloid biology, ultimately aiming to transform cold tumors into hot ones. Through strategic partnerships and collaborations, the company is dedicated to advancing immuno-oncology and expanding the promise of immunotherapy.
Generated from the website